{
    "nctId": "NCT02020291",
    "briefTitle": "Phase I Study to Evaluate Safety, Tolerability, Anti-Tumour Activity and PK Profiles of Foxy-5 in Metastatic Breast, Colon or Prostate Cancer",
    "officialTitle": "Phase I Dose Escalating Study to Evaluate the Safety, Tolerability, Anti-Tumour Activity and Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients With Metastatic Breast, Colon or Prostate Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer, Colorectal Cancer, Prostate Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 31,
    "primaryOutcomeMeasure": "Safety and tolerability of Foxy-5",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Males and females of at least 18 years of age\n* Histologically/cytologically documented diagnosis of metastatic breast, colon or prostate cancer, refractory to standard therapy or for which no curative therapy exists\n* Loss of or reduced Wnt-5a protein expression in primary or metastatic tumour cells, characterised by IHC analysis\n* Eastern Cooperative Oncology Group (ECOG) performance status of \\<= 1\n* Life expectancy of at least 3 months\n* Unresectable disease, i.e. the metastases cannot be surgically removed with a curative intent\n* \\>= 4 weeks must have elapsed since the patient has received any other IMP\n* \\>=4 weeks must have elapsed since the patient has received any anti cancer treatment; including radiotherapy (except for single dose of palliative radiotherapy), cytotoxic chemotherapy, biologic agents or targeted therapy\n* \\>= 2 weeks must have elapsed since any prior surgery or therapy with bone marrow stimulating factors\n* Adequate haematological functions as defined by:\n* Absolute neutrophil count \\>= 1.5 10E9/L\n* Platelets \\>= 100 10E9/L\n* Hemoglobin \\>= 5.6 mmol/L\n* Adequate hepatic function as defined by:\n* Total bilirubin \\<= 1.5 x the upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) \\<= 2.5 x ULN\\*\n* Alanine aminotransferase (ALT) \\<= 2.5 x ULN\\*\n\n  \\* For patients with liver metastasis adequate hepatic function is defined by AST \\<= 5 x ULN and ALT \\<= 5 ULN.\n* Adequate renal function as defined by Serum creatinine \\<= 1,5 x ULN\n* Provision of written informed consent\n* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures\n* Sexually active males and females of child-producing potential, must use adequate contraception (intrauterine devices, hormonal contraceptives (contraceptive pills, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release) or diaphragm always with spermicidal jelly and a male condom) for the study duration and at least six months afterwards\n\nExclusion Criteria:\n\n* Active uncontrolled bleeding or bleeding diathesis (e.g., active peptic ulcer disease)\n* Any active infection requiring antibiotic treatment\n* Known infection with human immunodeficiency virus (HIV) or hepatitis virus\n* Active heart disease including myocardial infarction or congestive heart failure within the previous 6 months, symptomatic coronary artery disease, or symptomatic arrhythmias currently requiring medication\n* Known or suspected active central nervous system (CNS) metastasis. (Patients stable 8 weeks after completion of treatment for CNS metastasis are eligible)\n* Impending or symptomatic spinal cord compression or carcinomatous meningitis\n* Requiring immediate palliative surgery and/or radiotherapy\n* Pre-existing neuropathy, i.e., Grade \\>2 neuromotor or neurosensory toxicity\n* Participation in other clinical studies within 4 weeks of first dose of study treatment\n* History of severe allergic or hypersensitive reactions to excipients\n* Pregnant or breastfeeding women\n* Chronic immunosuppressant use (e.g. systemic steroids for treatment of autoimmune disease)\n* History of second malignancy, including histologically confirmed diagnosis of malignant melanoma except for carcinoma in situ or basal cell carcinoma\n* Severe or uncontrolled chronic or uncontrolled systemic disease (e. g. severe respiratory or cardiovascular disease)\n* Other medications or conditions that in the Investigator's opinion would contraindicate study participation of safety reasons or interfere with the interpretation of study results",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}